MMP1 and hepatocellular carcinoma: Although response to MMP1-related immunotherapy was reported in melanoma (all group, P = 0.0458; MAPKi group, P = 0.0355) and urothelial cancer (all group, P = 0.0168; smoking group, P = 0.0132), its correlation or lack of in HCC has not been reported in any cohort studies thus far (Fig. 11C).